✦ LIBER ✦

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

✍ Scribed by Marjorie M Luckey; Nigel Gilchrist; Henry G Bone; Michael W Davie; Tobias J de Villiers; Mei Wu; Anastasia G Daifotis; Arthur C Santora; John J Orloff

Book ID: 117191670
Publisher: Lippincott Williams and Wilkins
Year: 2003
Tongue: English
Weight: 198 KB
Volume: 101
Category: Article
ISSN: 0029-7844
DOI: 10.1016/s0029-7844(03)00008-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic effects of alendronate 35 mg

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

✍ Shinji Uchida; Tadaaki Taniguchi; Takafumi Shimizu; Taro Kakikawa; Kotoba Okuyam 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 721 KB

Once-weekly alendronic acid more effecti

Once-weekly alendronic acid more effective than daily risedronic acid in the treatment of postmenopausal osteoporosis

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Therapeutic equivalence of alendronate 7

Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

✍ Schnitzer, T.; Bone, H. G.; Crepaldi, G.; Adami, S.; McClung, M.; Kiel, D.; Fels 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 156 KB

A comparative study of the effects of da

A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients

✍ Toru Yoshioka, Nobukazu Okimoto, Ken Okamoto… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 261 KB

The therapeutic response to Alendronate

The therapeutic response to Alendronate in postmenopausal Chinese women with osteoporosis and N740N polymorphism of low density lipoprotein receptor related protein 5 (LRP5) gene

✍ Wenzhen Fu; Yaohua Ke; Zhenlin Zhang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi